Nastech's parathyroid hormone nasal spray well tolerated in phase 1 study

By Lisa Kerner

Erie, Pa., April 28 - Nastech Pharmaceutical Co. Inc. said its parathyroid hormone (PTH1-34) nasal spray was well tolerated and had a similar pharmacokinetic profile to the existing injectable product Forteo (teriparatide) in a phase 1 study.

The company will present results from the study at the American Association of Clinical Endocrinologists Annual Meeting in Chicago.

In the phase 1 study, 12 healthy human subjects between the ages of 20 and 40 received a single 20 ug subcutaneous injection of teriparatide followed by successive doses of an intranasal formulation of PTH1-34.

There were no clinically significant changes from baseline for vital signs, electrocardiograms, nasal examinations, or laboratory evaluations, according to a company news release.

PTH1-34 is a fragment of the naturally occurring human parathyroid hormone that regulates calcium and phosphorus metabolism.

Nastech, a Bothell, Wash., pharmaceutical company, develops products based on proprietary molecular drug delivery technologies for respiratory disease, inflammatory conditions, obesity and osteoporosis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.